^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    SelectMDx

    Company:
    MDxHealth
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1). The test provides binary results that, when combined with the patient’s clinical risk factors, help the physician determine whether: The patient may benefit from a biopsy and early prostate detection, or The patient can avoid a biopsy and return to routine screening
    Cancer:
    Prostate Cancer
    Gene:
    DLX1 (Distal-Less Homeobox 1), HOXC6 (Homeobox C6)
    Method:
    Liquid biopsy
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    10/13/15
    PC
    -
    CE